Trial Profile

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solanezumab (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Acronyms A4
Sponsors Eli Lilly and Company

Most Recent Events

01 Oct 2023 Status changed from active, no longer recruiting to completed.
20 Jul 2023 Results presented at the Alzheimer's Association International Conference 2023
20 Jul 2023 Results (n=1641) assessing Functional connectivity of the frontoparietal control network is positively associated with cognition, independent of amyloid and tau burden presented at the Alzheimer's Association International Conference 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com